Iridex Corp
IRIXIridex Corporation (IRIX) is a medical device company specializing in ophthalmic surgical and laser therapy systems. Founded in 1984, the company develops innovative laser products for the treatment of ocular diseases, primarily focusing on minimally invasive procedures for conditions such as glaucoma, retinal therapy, and diabetic retinopathy. Iridex's products are used by ophthalmologists worldwide to improve patient outcomes through precise and effective laser treatments.
Company News
Iridex Corporation announced its intent to relocate its headquarters from Mountain View, California to San Jose, California. The company signed a non-binding letter of intent for a 31,000 square feet location on January 26, 2026, expecting to generate approximately $0.4 million in savings for fiscal year 2026 and $0.6 million in annualized saving...
An independent study demonstrated that retreatment with MicroPulse® transscleral laser technology can safely reduce intraocular pressure in glaucoma patients, with IOP reductions ranging from 25% to 35% across different patient groups.
Medical device company Iridex reported Q2 2025 results with modest revenue growth, narrower net loss, and positive adjusted EBITDA, driven by cost control and operational discipline.
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, commented on recent stock price volatility, stating that there have been no material changes to its operating or financial condition.
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, announces plans to release its Q4 and full-year 2024 financial results and provide a business update on March 27, 2025.
